Denali Therapeutics (DNLI)

Revenue in 2024 (TTM): N/A

In 2023 the company made a revenue of HK$2.58 Billion an increase over the revenue in the year 2022 that were of HK$0.84 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Denali Therapeutics from 2017 to 2024

Annual revenue

Year	Revenue	Change
2024 (TTM)	N/A	-100%
2023	HK$2.58 B	204.62%
2022	HK$0.84 B	123.34%
2021	HK$0.37 B	-85.42%
2020	HK$2.60 B	1152.38%
2019	HK$0.20 B	-79.46%
2018	HK$1.01 B
2017	N/A

Revenue for similar companies or competitors

Company	Revenue	Revenue differencediff.	Country
Novocure NVCR	HK$4.48 B	N/A	Jersey
Novavax NVAX	HK$6.58 B	N/A	🇺🇸 USA
Organovo ONVO	HK$0.8 M	N/A	🇺🇸 USA
Orchard Therapeutics ORTX	HK$0.16 B	N/A	🇬🇧 UK

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Revenue for Denali Therapeutics (DNLI)

Revenue in 2024 (TTM): N/A